VDAC1 and triple-negative breast carcinoma: Previously, we showed that silencing VDAC1 expression using human-specific siRNA (si-hVDAC1) resulted in the inhibition of cancer cell growth, both in vitro and in vivo in mouse intracranial and xenograft models of human glioblastoma, lung cancer, triple negative breast cancer, mesothelioma, and bladder cancers [17,18,19,20,22,23,28].